MA51664B1 - Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide - Google Patents

Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide

Info

Publication number
MA51664B1
MA51664B1 MA51664A MA51664A MA51664B1 MA 51664 B1 MA51664 B1 MA 51664B1 MA 51664 A MA51664 A MA 51664A MA 51664 A MA51664 A MA 51664A MA 51664 B1 MA51664 B1 MA 51664B1
Authority
MA
Morocco
Prior art keywords
cyclopropylmethyl
isoxazole
pyrimidin
difluoro
cyclopropyl
Prior art date
Application number
MA51664A
Other languages
English (en)
Other versions
MA51664A (fr
Inventor
Philippe Guerry
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA51664A publication Critical patent/MA51664A/fr
Publication of MA51664B1 publication Critical patent/MA51664B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des formes cristallines de l'acide (3s,4s)-1- cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)- amide ; des procédés pour leur préparation, et des compositions pharmaceutiques contenant de telles formes cristallines. Le composé agit en tant que modulateur du récepteur cxcr7 et est donc utile pour le traitement du cancer.
MA51664A 2018-01-26 2019-01-25 Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide MA51664B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018051938 2018-01-26
PCT/EP2019/051819 WO2019145460A1 (fr) 2018-01-26 2019-01-25 Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide

Publications (2)

Publication Number Publication Date
MA51664A MA51664A (fr) 2021-05-05
MA51664B1 true MA51664B1 (fr) 2024-05-31

Family

ID=65139016

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51664A MA51664B1 (fr) 2018-01-26 2019-01-25 Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide

Country Status (18)

Country Link
US (1) US11339148B2 (fr)
EP (1) EP3743422B1 (fr)
JP (1) JP7076010B2 (fr)
KR (1) KR102502046B1 (fr)
CN (1) CN111683945B (fr)
AU (1) AU2019212888B8 (fr)
BR (1) BR112020015024A2 (fr)
CA (1) CA3088478A1 (fr)
CL (1) CL2020001928A1 (fr)
EA (1) EA202091746A1 (fr)
IL (1) IL276227B1 (fr)
MA (1) MA51664B1 (fr)
MX (1) MX2020007881A (fr)
PH (1) PH12020551121A1 (fr)
SG (1) SG11202006943TA (fr)
TW (1) TWI822724B (fr)
UA (1) UA125327C2 (fr)
WO (1) WO2019145460A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490986B1 (fr) 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050024A2 (fr) 2002-11-27 2004-06-17 Incyte Corporation Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005032490A2 (fr) 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Diamines cycliques et derives comme inhibiteurs du facteur xa
BRPI0607756A2 (pt) 2005-02-18 2010-05-18 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos
WO2009011850A2 (fr) * 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (fr) 2011-12-09 2013-06-13 Cadila Healthcare Limited Composés inhibiteurs de rénine
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
PT2925745T (pt) * 2012-11-29 2018-08-08 Chemocentryx Inc Antagonistas de cxcr7
CN105263924B (zh) 2013-05-30 2018-10-19 爱杜西亚制药有限公司 Cxcr7受体调节剂
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (fr) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Composés immunomodulateurs thérapeutiques
KR20170047397A (ko) * 2014-09-10 2017-05-04 에피자임, 인코포레이티드 치환된 피페리딘 화합물
AU2015315173A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine compounds
WO2016087370A1 (fr) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Modulateurs du récepteur cxcr7
EP3490986B1 (fr) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine

Also Published As

Publication number Publication date
AU2019212888A8 (en) 2024-01-04
PH12020551121A1 (en) 2021-05-31
BR112020015024A2 (pt) 2021-01-19
WO2019145460A1 (fr) 2019-08-01
EP3743422B1 (fr) 2024-03-13
TW201932460A (zh) 2019-08-16
CL2020001928A1 (es) 2020-12-18
IL276227B1 (en) 2024-06-01
CA3088478A1 (fr) 2019-08-01
EP3743422A1 (fr) 2020-12-02
JP2021511382A (ja) 2021-05-06
JP7076010B2 (ja) 2022-05-26
UA125327C2 (uk) 2022-02-16
MA51664A (fr) 2021-05-05
CN111683945B (zh) 2023-11-10
CN111683945A (zh) 2020-09-18
SG11202006943TA (en) 2020-08-28
KR102502046B1 (ko) 2023-02-20
MX2020007881A (es) 2022-06-02
EA202091746A1 (ru) 2020-11-26
KR20200116115A (ko) 2020-10-08
AU2019212888A1 (en) 2020-09-10
IL276227A (en) 2020-09-30
EP3743422C0 (fr) 2024-03-13
AU2019212888B2 (en) 2023-12-21
TWI822724B (zh) 2023-11-21
US11339148B2 (en) 2022-05-24
AU2019212888B8 (en) 2024-01-04
US20210115033A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
TN2011000316A1 (fr) Derives de sulfonamides
MA39582B1 (fr) Composés de 6,7-dihydropyrazolo [1,5-?]pyrazin -4 (5h)-one et leur utilisation en tant que modulateurs négatifs allostériques des récepteurs métabotropiques du glutamate
MA51664B1 (fr) Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA31419B1 (fr) Derives de pyridine
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
MA34308B1 (fr) Triazolopyridines substituées
MA49127B1 (fr) Dérivés d'indole n-substitués
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA52946B1 (fr) Composés
EA201290534A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов
MX2022016357A (es) Derivados de tetrazol como inhibidores de trpa1.
EA202092326A1 (ru) Производные буметанида для лечения гипергидроза
MA39750A (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA56508B1 (fr) Inhibiteur de l'egfr pour le traitement du cancer
MA52375A1 (fr) Inhibiteurs de cdk8/19